ArticleJPGN reports2026
Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction-associated steatotic liver disease treated with semaglutide: A case series.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30%-40% of youth with obesity and lacks approved pharmacologic therapies. In this single-center retrospective case series at a tertiary care safety-net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index: 50.8 kg/m²) treated with semaglutide for ≥3 months. Baseline liver enzymes and fibrosis marker (mean ± standard deviation) included alanine aminotransferase (ALT): 107.4 ± 26.8 IU/L, aspartate aminotransferase (AST): 64.6 ± 16.2 IU/L, and AST to platelet ratio index (APRI): 0.41 ± 0.07. After treatment, values decreased to ALT: 69.0 ± 17.9 IU/L, AST: 43.6 ± 8.8 IU/L, and APRI: 0.28 ± 0.05. Reduction in ALT (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.